Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine
Allergy and Immunology | Bacterial Infections and Mycoses | Endocrine System Diseases | Immunology and Infectious Disease | Infectious Disease | Microbiology | Nutritional and Metabolic Diseases
Objectives: To study the association of Tissue inhibitors of matrix metalloproteinases (TIMP) levels with tuberculosis-diabetes comorbidity (TB-DM) comorbidity at baseline and in response to anti-TB treatment (ATT).
Methods: We examined the levels of TIMP-1, -2, -3 and -4 in pulmonary tuberculosis alone (TB) or TB-DM at baseline and after ATT.
Results: TIMP-1, -3 and -4 were significantly increased in TB-DM compared to TB at baseline and after ATT. ATT resulted in a significant reduction in TIMP-2 and -3 levels and a significant increase in TIMP-1 in both TB and TB-DM. TIMP-1, -3 and -4 were also significantly increased in TB-DM individuals with bilateral, cavitary disease and also exhibited a positive relationship with bacterial burden in TB-DM and HbA1c in all TB individuals. Within the TB-DM group, those known to be diabetic before incident TB (KDM) exhibited higher levels of TIMP-1, -2, -3 and -4 at baseline and TIMP-2 at post-treatment compared to those newly diagnosed with DM (NDM). KDM individuals on metformin treatment exhibited lower levels of TIMP-1, -2 and -4 at baseline and of TIMP-4 at post-treatment.
Conclusions: TIMP levels were elevated in TB-DM, associated with disease severity and bacterial burden, correlated with HbA1c levels and modulated by duration of DM and metformin treatment.
Diabetes mellitus, Mycobacterium tuberculosis, Tissue inhibitors of metalloproteinases
Rights and Permissions
Copyright © 2021 The Author(s). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
DOI of Published Version
Kumar NP, Moideen K, Viswanathan V, Sivakumar S, Hissar S, Kornfeld H, Babu S. Effect of anti-tuberculosis treatment on the systemic levels of tissue inhibitors of metalloproteinases in tuberculosis - Diabetes co-morbidity. J Clin Tuberc Other Mycobact Dis. 2021 Apr 22;23:100237. doi: 10.1016/j.jctube.2021.100237. PMID: 33997311; PMCID: PMC8100611. Link to article on publisher's site
Journal of clinical tuberculosis and other mycobacterial diseases
Kumar NP, Moideen K, Viswanathan V, Sivakumar S, Hissar S, Kornfeld H, Babu S. (2021). Effect of anti-tuberculosis treatment on the systemic levels of tissue inhibitors of metalloproteinases in tuberculosis - Diabetes co-morbidity. Open Access Publications by UMass Chan Authors. https://doi.org/10.1016/j.jctube.2021.100237. Retrieved from https://escholarship.umassmed.edu/oapubs/4690
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.
Allergy and Immunology Commons, Bacterial Infections and Mycoses Commons, Endocrine System Diseases Commons, Immunology and Infectious Disease Commons, Infectious Disease Commons, Microbiology Commons, Nutritional and Metabolic Diseases Commons